The Cancer Treatments Centers of America developed the vaccine.
It is a patient-specific vaccine, based on a patient's own tumor cells.
The vaccine will be used in combination with chemotherapy to boost its effectiveness, and put less stress on the patient's own immune system.
The CTCA expects to begin treating patients this summer.
It will be available to women whose cancer has returned after chemotherapy.
Ovarian cancer is a complex disease, difficult to diagnose and often resistant to chemotherapy.
More than 15-thousand women die every year from ovarian cancer.
Posts
